Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

234

Participants

Timeline

Start Date

July 29, 2015

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Breast Cancer
Interventions
DRUG

Goserelin+TAM+AI

Goserelin 3.6mg subcutaneous injection per 4 weeks, for 16-20weeks. TAM 10mg oral twice a day for the first four weeks(to wait the Goserelin start to work in body) than change to AI 1mg oral once a day with Goserelin for the next 12-16 weeks.

DRUG

Epirubicin+CTX+5-Fu

Epirubicin(80-100 mg/m2 Q21 days) + CTX(600 mg/m2 Q 21days) + 5-Fu (600 mg/m2 Q21 days or 200 mg/m2 •day from Day1 to day 21) for four to six cycles.

Trial Locations (1)

Unknown

RECRUITING

Beijing Cancer Hospital Breast Center, Beijing

All Listed Sponsors
lead

Peking University

OTHER